m6A Target Gene Information

General Information of the m6A Target Gene (ID: M6ATAR00985)
Target Name Circ_TET2
Gene Name Circ_TET2
Full List of Crosstalk(s) between m6A Modification and Epigenetic Regulation Related to This Regulator
Non-coding RNA
m6A Regulator: YTH domain-containing protein 1 (YTHDC1)
 Regulator Info 
In total 3 item(s) under this m6A regulator
Crosstalk ID: M6ACROT05719
 Crosstalk Info 
Epigenetic Regulator Circ_TET2
Regulated Target Heterogeneous nuclear ribonucleoprotein C (HNRNPC)
Crosstalk relationship m6A → ncRNA
Disease Chronic lymphocytic leukemia
 Disease Info 
Drug CP028
 Drug Info 
Crosstalk ID: M6ACROT05720
 Crosstalk Info 
Epigenetic Regulator Circ_TET2
Regulated Target Heterogeneous nuclear ribonucleoprotein C (HNRNPC)
Crosstalk relationship m6A → ncRNA
Disease Chronic lymphocytic leukemia
 Disease Info 
Drug dactolisib
 Drug Info 
Crosstalk ID: M6ACROT05721
 Crosstalk Info 
Epigenetic Regulator Circ_TET2
Regulated Target Heterogeneous nuclear ribonucleoprotein C (HNRNPC)
Crosstalk relationship m6A → ncRNA
Disease Chronic lymphocytic leukemia
 Disease Info 
Drug perhexiline
 Drug Info 
m6A Regulator: RNA binding protein X (RBMX)
 Regulator Info 
In total 3 item(s) under this m6A regulator
Crosstalk ID: M6ACROT05722
 Crosstalk Info 
Epigenetic Regulator Circ_TET2
Regulated Target Heterogeneous nuclear ribonucleoprotein C (HNRNPC)
Crosstalk relationship m6A → ncRNA
Disease Chronic lymphocytic leukemia
 Disease Info 
Drug CP028
 Drug Info 
Crosstalk ID: M6ACROT05723
 Crosstalk Info 
Epigenetic Regulator Circ_TET2
Regulated Target Heterogeneous nuclear ribonucleoprotein C (HNRNPC)
Crosstalk relationship m6A → ncRNA
Disease Chronic lymphocytic leukemia
 Disease Info 
Drug dactolisib
 Drug Info 
Crosstalk ID: M6ACROT05724
 Crosstalk Info 
Epigenetic Regulator Circ_TET2
Regulated Target Heterogeneous nuclear ribonucleoprotein C (HNRNPC)
Crosstalk relationship m6A → ncRNA
Disease Chronic lymphocytic leukemia
 Disease Info 
Drug perhexiline
 Drug Info 
References
Ref 1 Wilms' tumor protein 1 (WT1) peptide vaccination in AML patients: predominant TCR CDR3Beta sequence associated with remission in one patient is detectable in other vaccinated patients. Cancer Immunol Immunother. 2012 Mar;61(3):313-22. doi: 10.1007/s00262-011-1099-y. Epub 2011 Sep 7.